Changes in BMI, Weight Linked to Survival in Endometrial Cancer
Changes in weight and BMI were associated with disease-free and overall survival.
Endometrial Cancer
Pembrolizumab Monotherapy Promising for MSI-H Advanced Endometrial Cancer
The duration of response was more than 3 years in 68% of patients.
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced Endometrial Cancer
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
Model More Accurately Predicts Outcomes of Radiotherapy in Cancer Patients
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
Radiomics ‘Not Ready for Prime Time’ in Endometrial Cancer
More research is needed before radiomics can be used in clinical practice, according to researchers.
Survival Disparities in Endometrial Cancer Persist Despite Equal Access to Care
Factors other than access may affect differences in survival, according to researchers.
TVUS ET Screening Misses More Cases of Endometrial Cancer in Black Women Than in White Women
The disparity is due to the greater prevalence of fibroids and nonendometrioid histologic type in Black women, according to researchers.
Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women
Data showed increases in endometrial cancer and obesity in women younger than 40.
Combination Anlotinib and Sintilimab Exhibits Antitumor Activity in Advanced Endometrial Cancer
Nearly three-quarters of patients responded to treatment.
Lynch Syndrome, Recurrence-Free Survival in Endometrial Cancer
There was a trend of different 5-year RFS among the groups, with the shortest among patients with MLH1-hypermethylated disease at 78.6% compared with 95.5% among patients with other causes of MMRd.
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...